Naltrexone–bupropion (Mysimba) in management of obesity: A systematic review and meta‐analysis of unpublished clinical study reports-Reference-Cited by-同舟云学术

Naltrexone–bupropion (Mysimba) in management of obesity: A systematic review and meta‐analysis of unpublished clinical study reports

Published:2020-02-04 Issue:4 Volume:86 Page:646-667
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Onakpoya Igho J.¹^ORCID,Lee Joseph J.¹,Mahtani Kamal R.¹,Aronson Jeffrey K.¹^ORCID,Heneghan Carl J.¹

Affiliation:

1. Centre for Evidence‐Based Medicine, Nuffield Department of Primary Care Health Sciences, Radcliffe Observatory QuarterUniversity of Oxford Oxford UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14210

Reference33 articles.

1. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013

2. World Health Organization.Obesity and overweight. Key facts.16 February 2018.https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight[Accessed 12 February 2019]

3. Cost-Effectiveness of Fiscal Policies to Prevent Obesity

4. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review

5. Effect of combined naltrexone and bupropion therapy on the brain’s reactivity to food cues

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Obesity and cardiovascular disease: an ESC clinical consensus statement;European Journal of Preventive Cardiology;2024-08-30

2. Obesity and cardiovascular disease: an ESC clinical consensus statement;European Heart Journal;2024-08-30

3. Treatment with liraglutide or naltrexone-bupropion in patients with genetic obesity: a real-world study;eClinicalMedicine;2024-08

4. The Effect of KSK-94, a Dual Histamine H3 and Sigma-2 Receptor Ligand, on Adipose Tissue in a Rat Model of Developing Obesity;Pharmaceuticals;2024-07-01

5. Correction to “Naltrexone‐bupropion (Mysimba) in management of obesity: A systematic review and meta‐analysis of unpublished clinical study reports.”;British Journal of Clinical Pharmacology;2024-04-08